政策动向 默沙东新型抗菌药物锐可博®在华上市 5月12日，默沙东宣布，其新型碳青霉烯/酶抑制剂复合制剂锐可博®（注射用亚胺西瑞）已正式在中国 境内上市，适用于治疗18岁及以上患者由敏感革兰阴性菌引起的下列感染：医院获得性细菌性肺炎和呼 吸机相关性细菌性肺炎（HABP/VABP）；治疗药物选择有限或无替代治疗的复杂性尿路感染（cUTI） （包括肾盂肾炎）；治疗药物选择有限或无替代治疗的复杂性腹腔内感染（cIAI）。首批药物已在默沙 东中国杭州工厂完成包装，实现本土首发。 资本市场 晶泰控股拟2.5亿元收购上海四维医学科技90%股权 5月11日，晶泰控股宣布以总计2.5亿元对价收购国内最大规模的远程心电图(ECG)诊断服务解决方案企 业——上海四维医学科技有限公司(四维医学)90%的股权，上海交通大学拥有剩余10%股权。收购后， 四维医学作为晶泰控股的子公司，将支撑晶泰科技在 AI医疗领域的重要业务板块，并赋能其新药研发 业务。 怡和嘉业与翰宇药业、翰宇健康签署合作协议 黑龙江八部门联合治理"神医"广告乱象 为贯彻落实国家市场监管总局《关于维护广告市场秩序营造良好消费环境的通知》和重点领域广告监管 工作部署会要求 ...

行业概览 2025/01 www.leadleo.com 2025年 医疗器械海外市场拓展现状剖析 及前景洞察 Medical Device Overseas Market Expansion Status Analysis and Prospect Insight in 2025 2025年医療機器海外市場拡大の現状分析と展望 报告标签：医疗耗材、IVD设备、医学影像设备、"一带一路"、RECP协作、AI医疗、 医疗器械集采、DRG/DIP、美国、马来西亚 主笔人：荆婧 报告提供的任何内容（包括但不限于数据、文字、图表、图像等）均系头豹研究院独有的高度机密性 文件（在报告中另行标明出处者除外）。 ，任何人不得以任何方式擅自 复制、再造、传播、出版、引用、改编、汇编本报告内容，若有违反上述约定的行为发生，头豹研究 院保留采取法律措施、追究相关人员责任的权利。头豹研究院开展的所有商业活动均使用"头豹研究院 "或"头豹"的商号、商标，头豹研究院无任何前述名称之外的其他分支机构，也未授权或聘用其他任何 第三方代表头豹研究院开展商业活动。 白皮书 | 2025/01 中国医疗器械海外市场拓展现状及前景 www.lea ...

（原标题：一则消息引发恒生创新药ETF、港股通创新药ETF下跌，多家机构看好创新药板块） 一则消息，港股、A股、日本创新药板块突发大跌。 截至今日收盘，恒生创新药ETF、港股通创新药ETF、港股创新药50ETF、恒生医疗ETF、港股创新药 ETF基金跌超4%。 消息面上，特朗普又有新动作，他将于周一签署一项行政命令，让美国的处方药和药品价格将立即降低 30%至80%。 兴业证券继续看好创新+自主可控，并建议重点关注具备较好成长性和产业逻辑的细分领域。创新+国 际化仍是核心关键词，重点关注创新药，以及基本面开始改善的创新药产业链。同时，随着deepseek等 技术发展，我们认为AI医疗有望成为2025年医药板块的重要方向之一。此外，医疗器械2025年亦有望 迎来改善；2025年若经济基本面预期转好，消费医疗领域（中药OTC、医疗服务与连锁药店等）也有望 实现回升。 开源证券指出，疫情高基数、医疗合规化、产业内部调结构等多因素搅动下，近两年医药板块整体经营 有所波动：2025年第一季度，医药板块整体收入增速-6.13%，归母净利润增速-9.68%。产业调整已接近 尾声，医药指数已先行企稳回升：受行业整体经营承压， ...

Core Insights - The article highlights the significant potential of AI in the healthcare sector, particularly in remote medical services and diagnostics, with a focus on the acquisition of Shanghai Siwei Medical Technology Co., Ltd. by Jingtai Holdings for 250 million yuan [1][2][3] Company Summary - Jingtai Holdings has acquired 90% of Shanghai Siwei Medical, the largest remote ECG diagnostic service provider in China, to enhance its AI healthcare business and support drug development [1][2] - The acquisition will enable Jingtai to integrate clinical, molecular, and imaging data to develop precise and efficient remote diagnostic tools for cardiovascular diseases [2][6] - Jingtai aims to leverage Siwei's extensive structured ECG data and clinical experience to create a high-efficiency remote medical and AI-assisted diagnostic platform [6][7] Industry Summary - Cardiovascular diseases are the leading cause of death in China, accounting for over 45% of total deaths, with a significant market for ECG monitoring, estimated at 21 billion yuan [3][4] - The remote ECG testing market is projected to reach 10 billion yuan by 2022, driven by the increasing demand for advanced healthcare solutions amid a shortage of specialized medical professionals [3][4] - Government policies, such as the "Healthy China 2030" initiative, are promoting the integration of AI in healthcare, encouraging the development of remote medical services [4][5]

从细分赛道来看，创新药成为医药行情中"最亮眼的存在"。以年内回报率超38%的中银港股通医药为 例，截至一季度末，该基金重仓了翰森制药、科伦博泰生物-B、康方生物、百济神州、信达生物、康诺 亚-B、和黄医药、再鼎医药、荣昌生物、诺诚健华。从持仓方向上看，创新药是该基金的重仓方向，多 只重仓股在一季度的涨幅超50%。 然而，医药主题基金内部的业绩分化程度尤其引人注目。同样是重仓医疗赛道，年内回报率最低的基金 跌幅已经超13%，与业绩最好的基金相差50个百分点。以某沪上公募机构旗下的医药主题基金为例，该 基金年内跌幅超过12%。截至一季度末，该基金重仓了多只医疗器械和医疗服务类股票。然而，有的重 仓股自今年1月份开始便一路震荡下跌，有的重仓股尽管在2月份涨幅明显，但在3月份亦经历了明显调 整，回吐不少涨幅。 相关产品的基金经理在一季报中表示，自己在一季度减配了去年底挖掘的一批涨幅较明显的创新药标 的，并且增加了AI医疗相关标的配置比例。"虽然3月份AI医疗标的出现调整，但是我们跟踪到整个医 疗产业链都非常重视并且在积极拥抱这次AI带来的产业变革。" 另一只跌幅超过10%的基金亦在一季度末重仓了多只医疗器械和医疗服务 ...

2025.05. 11 本文字数：2500，阅读时长大约4分钟 作者 | 第一财经 曹璐 美国"对等关税"政策发酵，全球贸易格局继续调整，成为资本市场近期关注的焦点。Wind数据显 示，截至5月9日，近一个月来机构调研热度飙升，2210家上市公司迎来3068次调研，以区间18个交 易日计算，平均每天有超过170次调研。 这轮调研热潮中，电子、机械设备、医药生物等三大板块成为机构重点关注的领域。立讯精密 （002475.SZ）、水晶光电（002273.SZ）等公司吸引超300家机构扎堆调研。此外，机构投资者在关 注企业财报业绩的同时，也重点聚焦了关税冲击下的海外布局、成本转嫁策略等关键问题。 "财报季后和增量政策空窗期，仍建议关注具有产业进展的科技方向。"金鹰基金权益研究部金达莱对 第一财经表示，AI应用、人形机器人、智能驾驶等新质生产力方向近期已有所反弹，随着财报落 地，AI大模型产业进展或带动其再度有所表现，日历效应下利于节后资金回流和科技成长风格的估 值修复。 近一个月3068次调研 针对关税影响问题，该公司在调研中表示，目前市场上更多的是情绪上的恐慌，但从企业实际经营的 角度来看，大多数出口美国的终端产 ...

美国"对等关税"政策发酵，全球贸易格局继续调整，成为资本市场近期关注的焦点。Wind数据显示， 截至5月9日，近一个月来机构调研热度飙升，2210家上市公司迎来3068次调研，以区间18个交易日计 算，平均每天有超过170次调研。 这轮调研热潮中，电子、机械设备、医药生物等三大板块成为机构重点关注的领域。立讯精密 （002475.SZ）、水晶光电（002273.SZ）等公司吸引超300家机构扎堆调研。此外，机构投资者在关注 企业财报业绩的同时，也重点聚焦了关税冲击下的海外布局、成本转嫁策略等关键问题。 "财报季后和增量政策空窗期，仍建议关注具有产业进展的科技方向。"金鹰基金权益研究部金达莱对第 一财经表示，AI应用、人形机器人、智能驾驶等新质生产力方向近期已有所反弹，随着财报落地，AI 大模型产业进展或带动其再度有所表现，日历效应下利于节后资金回流和科技成长风格的估值修复。 近一个月3068次调研 Wind数据显示，截至5月9日，近一个月有2210家上市公司接待了来自机构投资者的3068次调研，合计 接待来访机构家数达5.28万家。申万一级行业中，电子、机械设备、医药生物三大板块成为机构重点关 注领域，相关调 ...

Core Viewpoint - The company held its 2024 annual performance briefing, where it engaged with investors and addressed various inquiries regarding its business strategies and performance metrics. Group 1: Company Performance - In 2024, the company achieved total revenue of 1.349 billion yuan, representing a year-on-year growth of 16.93% [6] - The net profit attributable to shareholders was 113 million yuan, an increase of 11.54% year-on-year [6] - The company's proprietary drug business generated 283 million yuan in revenue, marking a 44.31% increase compared to the previous year [6][7] Group 2: Business Strategy - The company is focused on a management-style medical strategy, which has led to a revenue growth of 25%-30% in its pharmaceutical and medical services sectors [4] - The company aims to enhance its digital health management services, covering the entire patient lifecycle, to improve drug sales and patient compliance [4][7] - The company plans to optimize its liver disease patient management system in response to the "Healthy China 2030" initiative [4] Group 3: Market Position and Future Outlook - The domestic market accounted for 36.72% of revenue, while the international market contributed 63.28% in 2024 [4] - The company is committed to becoming a professional and international management-style medical group, focusing on liver cancer screening and management [4][7] - The company anticipates that the market for its products will enter a rapid growth phase following the approval of the MASH indication by the FDA [4][8] Group 4: Product and Service Development - The company has developed a full-cycle management solution for liver disease, integrating screening, diagnosis, and treatment [4][7] - The FibroScan Go and box products have been installed in 651 units globally, becoming new revenue growth points for the company [7] - The company is enhancing its marketing strategies for its proprietary drugs and expanding its e-commerce channels to sustain high growth rates [6][7]

Core Insights - The article highlights the continuous progress and strategic partnerships of Yidu Technology in the AI healthcare sector, including collaborations with major hospitals and participation in industry conferences [1][3][5] Group 1: Strategic Partnerships and Collaborations - Yidu Technology has established a comprehensive strategic partnership with Beijing Friendship Hospital to co-build a clinical research smart laboratory, focusing on the application of large model technology in medical research [1] - The company collaborated with Peking University Cancer Hospital to develop the "CACA Guideline Assistant," an AI tool that integrates authoritative treatment guidelines with hospital systems to enhance clinical decision-making [17] - Yidu Technology has been the main operator of the "Shenzhen Huiminbao" insurance program for three consecutive years, serving over 34 million insured users across multiple provinces [17] Group 2: Industry Engagement and Recognition - Yidu Technology was recognized as the only AI healthcare company in the "Best IR Hong Kong Company" category at the 8th New Fortune Best IR Awards, reflecting its strong governance and investor relations [19] - The company actively participated in various high-profile industry conferences, sharing insights on how AI can empower public health and improve clinical trial processes [3][5][9] Group 3: Technological Innovations - Yidu Technology showcased its AI-driven solutions for clinical trials at the Future XDC New Drug Conference, emphasizing its end-to-end intelligent research ecosystem [5] - The company reported a significant increase in patient recruitment accuracy for clinical trials, achieving over three times improvement through its self-developed medical large model [13] - The establishment of the "AI Middle Platform" aims to address challenges in hospital smart applications, facilitating a comprehensive digital transformation in healthcare [15] Group 4: Market Position and Future Outlook - Yidu Technology's core advantages in AI healthcare have been recognized by multiple securities firms, with ratings ranging from "Buy" to "Outperform the Market," indicating strong growth potential [22] - The company is positioned to benefit from the increasing adoption of AI technologies in Chinese hospitals, supported by government initiatives [22]

Investment Rating - The report maintains a "Positive" investment rating for the pharmaceutical industry [1] Core Insights - The pharmaceutical industry is experiencing continuous differentiation, with innovative drugs, raw materials, and CXO services performing well [3][4] - In 2024, 453 pharmaceutical companies achieved revenue of 2.46 trillion yuan, a year-on-year decline of 0.55%, and a net profit of 148.65 billion yuan, down 8.8% [3][71] - The first quarter of 2025 saw revenues of 601.7 billion yuan, a year-on-year decrease of 5.3%, and a net profit of 50.5 billion yuan, down 6.4% [3][71] Summary by Sections Innovative Drugs - In 2024, innovative drug companies generated revenue of 47.53 billion yuan, a year-on-year increase of 68.4, indicating strong momentum [3] - Domestic biotech companies are transitioning from R&D to commercialization, leading to significant revenue growth [3] Chemical Drugs - Chemical drug companies achieved revenue of 399.64 billion yuan in 2024, a year-on-year increase of 0.73%, with net profit rising by 13.25% [3] - The first quarter of 2025 saw revenues of 98.12 billion yuan, a year-on-year decline of 4.47% [3] Medical Devices - In 2024, the medical device sector generated revenue of 221.51 billion yuan, a year-on-year increase of 1.32%, but net profit fell by 13.22% [3] - The first quarter of 2025 reported revenues of 51.7 billion yuan, down 4.89% year-on-year [3] Biological Products - Blood products in 2024 generated revenue of 24.18 billion yuan, down 1.4%, while net profit increased by 14.47% [3] - Vaccine companies faced significant declines, with revenues dropping 45.3% in 2024 [3] Traditional Chinese Medicine - Traditional Chinese medicine saw revenues of 343.75 billion yuan in 2024, a decline of 4.1%, with net profit down 18.8% [3] Raw Materials - The raw materials sector achieved revenue of 122.58 billion yuan in 2024, a year-on-year increase of 7.9%, with net profit rising by 38.33% [3] Pharmaceutical Commerce - In 2024, pharmaceutical commerce companies generated revenue of 1.02531 trillion yuan, a year-on-year increase of 0.8%, but net profit fell by 13% [6] Medical Services - Medical service companies reported revenue of 77.66 billion yuan in 2024, down 2.0%, with net profit declining by 39.5% [6] CXO & Research Services - The CXO and research services sector generated revenue of 96.62 billion yuan in 2024, a year-on-year decrease of 3.92%, with net profit down 25.6% [6]